In the course of our studies on induction of early antigen (EA) and viral capsid antigen (VCA) in EBV-converted BJAB and Ramos cells and their respective clones and subclones, it became apparent that certain sera reacted with a distinct proportion of nuclei from EBV-converted lines after iododeoxyuridine induction followed by methanol fixation a few days later. No nuclear fluorescence was observed after acetone fixation or before or after induction and methanol fixation of noninfected BJAB, Ramos, P3HR-1, and Raji cells. The following is an account of these studies aiming at the characterization of the nuclear antigen and associated serological response in various groups of patients.
patients, TINA reactivity was observed three times: two patients suffered from "chronic" infectious mononucleosis, the other revealed persistent splenomegaly.
Two Epstein-Barr virus (EBV-negative tissue culture lines with bone-marrow-derived (B)-cell characteristics have been established from Burkitt lymphomas: the BJAB line from an EBV-negative African Burkitt's lymphoma (1) and the Ramos line (2) from an American tumor. Cells of both lines are readily infected by EBV, resulting in persistence of EBV DNA and in expression of Epstein-Barr nuclear antigen (EBNA) (2) (3) (4) . Conversion to EBNA expression has been achieved with EBV obtained from P3HR-1 cells (5) and B 95-8 cells (6) . EBV from P3HR-1 cells induced two EBNA patterns in both types of recipient cells upon prolonged cultivation: a faint granular fluorescence in the majority of cells and a more brilliant staining in a smaller percentage (4, 7) . In Hampar et al. (8) . Approximately 107 cells were sedimented and resuspended in regular tissue culture medium containing in addition 20,ug/ml of iododeoxyuridine, 0.4 ug/ml of aminopterin, and 14,ug/ml of hypoxanthine. After 24 hr of incubation at 370, the cells were washed twice with RPMI 1640 and then resuspended in fresh medium without the "induction cocktail." They were harvested at various intervals thereafter and examined for specific immunofluorescence.
EA induction by P3HR-1 Virus. Infection of cells by P3HR-1 virus was performed according to Henle et al. (9) and has been described in detail (7) . Differpntiation of R-and D-subspecificities of the EA complex followed the procedures described by Henle et al. (10) .
Immunofluorescence Studies. Air-dried smears of cells were fixed either in acetone or in methanol for 3 min at -20'. Indirect immunofluorescence was performed according to Henle and Henle (11) . Goat antiserum to human IgG was purchased from Behringwerke, Marburg, and used at a standard dilution of 1:40. The detailed procedure of anticomplement-immunofluorescence (4) pretitrated EBNA antisera were kindly provided by Werner Henle. The majority of sera from Hodgkin patients and from patients with lymphosarcomas and chronic lymphatic leukemias were furnished by Volker Diehl, Hannover, and W. Gallmeier, Essen. All other sera originated from the serum collection of this institute.
RESULTS

Induction of antigens in EBV-converted BJAB and
Ramos cells For these studies predominantly two clones of P3HR-1 EBVconverted BJAB cells were analyzed: clone A 7 revealing faint granular EBNA fluorescence in almost every cell, and clone B 1 showing brilliant EBNA staining, but segregating also EBNA-negative cells (7) . Treatment of both types of clones with the "induction cocktail" resulted in about 0.5% of cells in EA induction 3 days later. The same percentage of cells was stained, revealing the respective characteristic pattern, when reacted with sera of D-or R-reactivity.
Approximately 0.01% of cells were also VCA-positive, as ascertained by staining and comparative titrations with sera with VCA-reactivity only. In contrast to spontaneously induced P3HR-1 cells, VCA staining was frequently limited to the nucleus and was present as bright nuclear dots and spots.
Besides these staining reactions one serum (He), originating from a 70-yr-old patient with chronic lymphatic leukemia who also developed a melanoma, stained up to 6% of the nuclei of both clones after IUdR induction, depending on the time after induction (Fig. 1) Screening of sera for TINA reactivity Sera from 130 patients with tumors (predominantly of the lymphatic system) and 70 patients without malignant tumors were tested for TINA reactivity. Eighteen sera from tumorbearing patients were TINA-reactive at a dilution of 1:10 or higher. Two sera from "tumor-free" patients reacted also. Table  3 specifies the tumor patient group; the high number of positive sera among the nasopharyngeal carcinoma patients and possibly also of patients with immunoblastomas is striking. Three patients of the nontumor group revealing TINA reactivity suffered from "chronic" infectious mononucleosis (2) BJAB and Ramos cells also excludes the possibility that the anti-TINA response would be a nonspecific antinuclear activity such as is frequently observed in sera from patients with nasopharyngeal carcinoma (12) .
Several possibilities could be considered as far as the nature of TINA is concerned:
(i) TINA represents a "new" EBV-induced antigen. In this case it is difficult to interpret why it is not observed in other EBV-transformed lines with expression of various antigens.-It is also difficult to understand the nonreactivity against this antigen of a number of sera with high EBV-reactivity.
(H) TINA could be a "fetal" antigen. Nuclear localization and (ifi) TINA could be an antigen of an EBV-related, but different, herpesvirus present within BJAB and Ramos cells. Under these conditions TINA expression would be mediated by a helper effect of the induced EBV genomes. The high EA and VCA titers of TINA-reactive sera could be explained by the assumption that the agent responsible for TINA would also depend in vivo on EBV infection.
(iv) It is also possible that TINA is expressed by a virus totally different from EBV. This would be difficult to reconcile with the EBV reactivity of TINA-positive sera and almost requires the speculation that this agent also depends in vivo on helper effects by EBV-like agents.
On the basis of the available data it is presently impossible to decide which of these alternatives may be correct. The apparent prevalence of antibody response in tumor-bearing patients should stimulate further investigation of TINA. 
